• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Jump­ing ahead of As­traZeneca, Ab­b­Vie and J&J get a green light to mar­ket Im­bru­vi­ca/Rit­ux­an com­bo for rare lym­phoma

7 years ago
Pharma

No­var­tis wins a key OK for Kym­ri­ah, but con­tin­u­ing man­u­fac­tur­ing woes hob­ble roll­out — ri­val Gilead CAR-T breaks ...

7 years ago
Pharma

Es­pe­ri­on of­fers an­oth­er up­beat cut of piv­otal cho­les­terol da­ta for their com­bo, bumps back read­out for key safe­ty ...

7 years ago
R&D

Pfiz­er im­press­es car­dio crowd with mor­tal­i­ty and hos­pi­tal­iza­tion rates for tafamidis in AT­TR-CM -- but Al­ny­lam ...

7 years ago
R&D

Y-mAbs’ sto­ry comes in­to the light: a ship­ping ty­coon, the MSK re­searcher, a par­tial hold and a $92M IPO gam­ble

7 years ago
Financing

J&J, Bay­er fail at their sec­ond big at­tempt to spot­light a safe ben­e­fit for clot-buster Xarel­to in VTE

7 years ago
R&D

Chi­na Bi­o­log­ic re­jects $3.9B buy­out bid from ex-CEO; Leo Phar­ma bags atopic der­mati­tis drug for $17M up­front

7 years ago
News Briefing

E-Scape Bio in­stalls per­ma­nent CEO Julie Anne Smith; Fa­ther pass­es reins to son at Al­le­gro Oph­thalmics

7 years ago
Peer Review

Zai Lab bombs Phase IIa tri­al in atopic der­mati­tis, junks the pro­gram to shift re­sources to the pipeline

7 years ago
R&D

Out: NIH bud­get cuts. In: Alzheimer’s R&D as law­mak­ers boost pro­posed ’19 spend­ing to $2.3B

7 years ago
R&D

Shire wins a block­buster OK for pipeline star lanadelum­ab, boost­ing Take­da’s $62B takeover deal

7 years ago
Pharma

New­ly part­nered with blue­bird, Grit­stone seeks $80M IPO in fi­nal dash for clin­ic

7 years ago
Financing

Need a place­bo con­trol group for your next can­cer drug study? On­ly in cer­tain cir­cum­stances, says FDA

7 years ago
Pharma

Sang­amo re­searcher charged with in­sid­er trad­ing in lat­est round of SEC ac­cu­sa­tions lev­eled at a biotech ex­ec

7 years ago
People
Pharma

A new av­enue for di­et pill mak­ers? UC San Diego re­searchers un­cov­er root of lep­tin re­sis­tance

7 years ago
Discovery

New co-CEO named at WuXi; Bris­tol-My­ers gets pri­or­i­ty re­view for myelo­ma com­bo fea­tur­ing Em­plic­i­ti

7 years ago
News Briefing

Once laud­ed for its clin­i­cal suc­cess, Roche casts off car­dio pro­gram in­clacum­ab for a mere $2M to Glob­al Blood ...

7 years ago
Pharma

TCR deal fren­zy con­tin­ues as blue­bird antes up $30M for new Grit­stone al­liance

7 years ago
Pharma

Japan­ese bil­lion­aire Hi­roshi Mik­i­tani bankrolls As­pyr­i­an with a $150M mega-round, back­ing a glob­al roll­out plan for ...

7 years ago
Financing

Hit by sur­prise set­back, As­traZeneca scram­bles to ex­plain why its two-in-one COPD in­haler was beat­en by GSK ri­val

7 years ago
R&D

New­born bio­bet­ter, biosim­i­lar mak­er Mabpharm pitch­es the lat­est biotech IPO in Hong Kong

7 years ago
Financing
China

No­var­tis just boast­ed of a big PhI­II PI3K suc­cess, but here’s why we should hold our ap­plause — for now

7 years ago
R&D

Mag­ic mush­rooms might treat de­pres­sion? Pe­ter Thiel-backed Com­pass gets FDA OK to launch Phase IIb tri­als

7 years ago
Startups

Os­teoarthri­tis: FDA drafts guid­ance on de­vel­op­ing drugs, de­vices, bi­o­log­ics

7 years ago
Pharma
First page Previous page 1001100210031004100510061007 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.